1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 5
FEATURED COMPANIES
- Bausch Health
- Biofrontera
- F. Hoffmann-La Roche
- Mylan
- Sun Pharmaceutical
- MORE
The advancements in the field of oncology research is expected to help the market grow during the forecast period. The key players in the market are constantly developing medicines for various cancer indications. Analysts have predicted that the basal cell carcinoma therapeutics market will register a CAGR of around 6% by 2022.
Market Overview
Heavy investments to develop a strong R&D department
The market is expected to be driven by the heavy investments incurred to develop a strong R&D department for basal cell carcinoma treatment. Cancer is considered one of the most common causes of death across the globe, and the prevalence of cancer has witnessed a rapid surge in the past few years.
Higher demand for the surgical treatments for basal cell carcinoma
One of the major challenges faced by the global basal cell carcinoma therapeutics market is the availability of non-therapeutic treatment options such as surgeries.
For the detailed list of factors that will drive and challenge the growth of the basal cell carcinoma therapeutics market during the 2019-2023, view the report.
Competitive Landscape
The market appears to be concentrated and with the presence of few vendors including Bausch Health and Biofrontera the competitive environment is quite intense. Factors such as the advancements in the field of oncology research and heavy investments to develop a strong R&D department, will provide considerable growth opportunities to basal cell carcinoma therapeutics manufactures. Bausch Health, Biofrontera, Mylan, Sun Pharmaceutical, and F. Hoffmann-La Roche are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities. Some of the established pharmaceutical companies and various government organizations are investing profoundly in the R&D of novel therapies, which is currently dominated by biologic molecules due to their high effectiveness.’
Market Overview
Heavy investments to develop a strong R&D department
The market is expected to be driven by the heavy investments incurred to develop a strong R&D department for basal cell carcinoma treatment. Cancer is considered one of the most common causes of death across the globe, and the prevalence of cancer has witnessed a rapid surge in the past few years.
Higher demand for the surgical treatments for basal cell carcinoma
One of the major challenges faced by the global basal cell carcinoma therapeutics market is the availability of non-therapeutic treatment options such as surgeries.
For the detailed list of factors that will drive and challenge the growth of the basal cell carcinoma therapeutics market during the 2019-2023, view the report.
Competitive Landscape
The market appears to be concentrated and with the presence of few vendors including Bausch Health and Biofrontera the competitive environment is quite intense. Factors such as the advancements in the field of oncology research and heavy investments to develop a strong R&D department, will provide considerable growth opportunities to basal cell carcinoma therapeutics manufactures. Bausch Health, Biofrontera, Mylan, Sun Pharmaceutical, and F. Hoffmann-La Roche are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities. Some of the established pharmaceutical companies and various government organizations are investing profoundly in the R&D of novel therapies, which is currently dominated by biologic molecules due to their high effectiveness.’
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Bausch Health
- Biofrontera
- F. Hoffmann-La Roche
- Mylan
- Sun Pharmaceutical
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
PART 09: MARKET SEGMENTATION BY ROA
PART 11: REGIONAL LANDSCAPE
PART 13: DRIVERS AND CHALLENGES
Exhibit 01: Parent market
Exhibit 02: Global oncology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global basal cell carcinoma therapeutics market - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global basal cell carcinoma therapeutics market - Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Global basal cell carcinoma pipeline: Overview
Exhibit 20: Global basal cell carcinoma therapeutics market by RoA - Market share 2017-2022 (%)
Exhibit 21: Global basal cell carcinoma therapeutics market - Comparison by RoA
Exhibit 22: Global basal cell carcinoma therapeutics market by topical RoA - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global basal cell carcinoma therapeutics market by topical RoA - YoY growth 2018-2022 (%)
Exhibit 24: Global basal cell carcinoma therapeutics market by oral RoA - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global basal cell carcinoma therapeutics market by oral RoA - YoY growth 2018-2022 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Customer landscape
Exhibit 28: Global basal cell carcinoma therapeutics market - Market share by geography 2017-2022 (%)
Exhibit 29: Global basal cell carcinoma therapeutics market: Regional comparison
Exhibit 30: Basal cell carcinoma therapeutics market in Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Basal cell carcinoma therapeutics market in Americas - YoY growth 2018-2022 (%)
Exhibit 32: Basal cell carcinoma therapeutics market in EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Basal cell carcinoma therapeutics market in EMEA - YoY growth 2018-2022 (%)
Exhibit 34: Basal cell carcinoma therapeutics market in APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Basal cell carcinoma therapeutics market in APAC - YoY growth 2018-2022 (%)
Exhibit 36: Key leading countries: Overview
Exhibit 37: Global basal cell carcinoma therapeutics market - Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered - Overview
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Bausch Health: Overview
Exhibit 44: Bausch Health - Business segments
Exhibit 45: Bausch Health - Organizational developments
Exhibit 46: Bausch Health - Geographic focus
Exhibit 47: Bausch Health - Segment focus
Exhibit 48: Bausch Health - Key offerings
Exhibit 49: Bausch Health - Key customers
Exhibit 50: Biofrontera: Overview
Exhibit 51: Biofrontera - Organizational developments
Exhibit 52: Biofrontera - Geographic focus
Exhibit 53: Biofrontera - Key offerings
Exhibit 54: Biofrontera - Key customers
Exhibit 55: F. Hoffmann-La Roche: Overview
Exhibit 56: F. Hoffmann-La Roche - Business segments
Exhibit 57: F. Hoffmann-La Roche - Organizational developments
Exhibit 58: F. Hoffmann-La Roche - Geographic focus
Exhibit 59: F. Hoffmann-La Roche - Segment focus
Exhibit 60: F. Hoffmann-La Roche - Key offerings
Exhibit 61: F. Hoffmann-La Roche - Key customers
Exhibit 62: Mylan: Overview
Exhibit 63: Mylan - Business segments
Exhibit 64: Mylan - Organizational developments
Exhibit 65: Mylan - Geographic focus
Exhibit 66: Mylan - Segment focus
Exhibit 67: Mylan - Key offerings
Exhibit 68: Mylan - Key customers
Exhibit 69: Sun Pharmaceutical: Overview
Exhibit 70: Sun Pharmaceutical - Business segments
Exhibit 71: Sun Pharmaceutical - Organizational developments
Exhibit 72: Sun Pharmaceutical - Geographic focus
Exhibit 73: Sun Pharmaceutical - Segment focus
Exhibit 74: Sun Pharmaceutical - Key offerings
Exhibit 75: Sun Pharmaceutical - Key customers
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
- Basal cell carcinoma
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 09: MARKET SEGMENTATION BY ROA
- Segmentation by RoA
- Comparison by RoA
- Topical RoA - Market size and forecast 2017-2022
- Oral RoA - Market size and forecast 2017-2022
- Market opportunity by RoA
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Key leading countries
- Market opportunity
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Advancements in the field of oncology research
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bausch Health
- Biofrontera
- F. Hoffmann-La Roche
- Mylan
- Sun Pharmaceutical
- List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global oncology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global basal cell carcinoma therapeutics market - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global basal cell carcinoma therapeutics market - Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Global basal cell carcinoma pipeline: Overview
Exhibit 20: Global basal cell carcinoma therapeutics market by RoA - Market share 2017-2022 (%)
Exhibit 21: Global basal cell carcinoma therapeutics market - Comparison by RoA
Exhibit 22: Global basal cell carcinoma therapeutics market by topical RoA - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global basal cell carcinoma therapeutics market by topical RoA - YoY growth 2018-2022 (%)
Exhibit 24: Global basal cell carcinoma therapeutics market by oral RoA - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global basal cell carcinoma therapeutics market by oral RoA - YoY growth 2018-2022 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Customer landscape
Exhibit 28: Global basal cell carcinoma therapeutics market - Market share by geography 2017-2022 (%)
Exhibit 29: Global basal cell carcinoma therapeutics market: Regional comparison
Exhibit 30: Basal cell carcinoma therapeutics market in Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Basal cell carcinoma therapeutics market in Americas - YoY growth 2018-2022 (%)
Exhibit 32: Basal cell carcinoma therapeutics market in EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Basal cell carcinoma therapeutics market in EMEA - YoY growth 2018-2022 (%)
Exhibit 34: Basal cell carcinoma therapeutics market in APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Basal cell carcinoma therapeutics market in APAC - YoY growth 2018-2022 (%)
Exhibit 36: Key leading countries: Overview
Exhibit 37: Global basal cell carcinoma therapeutics market - Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered - Overview
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Bausch Health: Overview
Exhibit 44: Bausch Health - Business segments
Exhibit 45: Bausch Health - Organizational developments
Exhibit 46: Bausch Health - Geographic focus
Exhibit 47: Bausch Health - Segment focus
Exhibit 48: Bausch Health - Key offerings
Exhibit 49: Bausch Health - Key customers
Exhibit 50: Biofrontera: Overview
Exhibit 51: Biofrontera - Organizational developments
Exhibit 52: Biofrontera - Geographic focus
Exhibit 53: Biofrontera - Key offerings
Exhibit 54: Biofrontera - Key customers
Exhibit 55: F. Hoffmann-La Roche: Overview
Exhibit 56: F. Hoffmann-La Roche - Business segments
Exhibit 57: F. Hoffmann-La Roche - Organizational developments
Exhibit 58: F. Hoffmann-La Roche - Geographic focus
Exhibit 59: F. Hoffmann-La Roche - Segment focus
Exhibit 60: F. Hoffmann-La Roche - Key offerings
Exhibit 61: F. Hoffmann-La Roche - Key customers
Exhibit 62: Mylan: Overview
Exhibit 63: Mylan - Business segments
Exhibit 64: Mylan - Organizational developments
Exhibit 65: Mylan - Geographic focus
Exhibit 66: Mylan - Segment focus
Exhibit 67: Mylan - Key offerings
Exhibit 68: Mylan - Key customers
Exhibit 69: Sun Pharmaceutical: Overview
Exhibit 70: Sun Pharmaceutical - Business segments
Exhibit 71: Sun Pharmaceutical - Organizational developments
Exhibit 72: Sun Pharmaceutical - Geographic focus
Exhibit 73: Sun Pharmaceutical - Segment focus
Exhibit 74: Sun Pharmaceutical - Key offerings
Exhibit 75: Sun Pharmaceutical - Key customers
Note: Product cover images may vary from those shown
3 of 5
FEATURED COMPANIES
- Bausch Health
- Biofrontera
- F. Hoffmann-La Roche
- Mylan
- Sun Pharmaceutical
- MORE
The author of the report recognizes the following companies as the key players in the global basal cell carcinoma therapeutics market: Bausch Health, Biofrontera, Mylan, Sun Pharmaceutical, and F. Hoffmann-La Roche.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advancements in the field of oncology research.”
According to the report, one of the major drivers for this market is the Heavy investments to develop a strong R&D department.
Further, the report states that one of the major factors hindering the growth of this market is the higher demand for the surgical treatments for basal cell carcinoma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advancements in the field of oncology research.”
According to the report, one of the major drivers for this market is the Heavy investments to develop a strong R&D department.
Further, the report states that one of the major factors hindering the growth of this market is the higher demand for the surgical treatments for basal cell carcinoma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
- Bausch Health
- Biofrontera
- F. Hoffmann-La Roche
- Mylan
- Sun Pharmaceutical
Note: Product cover images may vary from those shown
5 of 5
LOADING...
